Clinical Trials Logo

Clinical Trial Summary

A Phase 2a study in men and women with early Alzheimer's disease to evaluate the pharmacodynamics, pharmacokinetics and safety of obicetrapib therapy.


Clinical Trial Description

This study will be a proof of concept, Phase 2a study in patients with early Alzheimer's disease (clinical diagnosis of Alzheimer's disease Stage 3 or 4 based on the National Institute on Aging Alzheimer's Association Research Framework criteria) to evaluate the Pharmacodynamic, cognitive effects, Pharmacokinetic, and safety and tolerability of obicetrapib therapy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05161715
Study type Interventional
Source NewAmsterdam Pharma
Contact
Status Completed
Phase Phase 2
Start date January 12, 2022
Completion date June 1, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04693520 - Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease Phase 2
Recruiting NCT05122598 - Development and Evaluation of Computerized Olfactory Training Program for Cognitive Decline in Early Alzheimer's Disease Phase 2
Active, not recruiting NCT04770220 - An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects Phase 3
Active, not recruiting NCT04777396 - A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Phase 3
Active, not recruiting NCT03887455 - A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease Phase 3
Recruiting NCT05531656 - A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease Phase 2
Recruiting NCT04599764 - High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Early Alzheimer's Disease N/A
Completed NCT02859207 - A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects Phase 1
Enrolling by invitation NCT06304883 - Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects Phase 3